One of the S&P 500’s big winners for Wednesday February 10 was Alexion Pharmaceuticals Inc. (ALXN) as the company’s stock climbed 3.17% to $140.79 on volume of 1.32 million shares.
The stock opened at $138.20 and saw an intraday low of $136.76 and an intraday high of $144.43. All told, the day saw a per-share gain of $4.33. The stock’s average daily volume of 1.65 million and 225.32 million shares outstanding. Alexion Pharmaceuticals Inc. now has a 50-day SMA is $170.23 and 200-day SMA is $173.70, and it has a 52-week high of $208.88 and a 52-week low of $130.51.
Alexion Pharmaceuticals Inc is a biopharmaceutical company engaged in serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
Based out of New Haven, CT, Alexion Pharmaceuticals Inc. has 2,924 employees and, after today’s trading, reached a market cap of $31.72 billion. The stock’s P/E Ratio is 179.6. Its P/S ratio is 11.81, P/B ratio is 3.84, and P/FCF ratio is -8.7.
For a complete fundamental analysis analysis of Alexion Pharmaceuticals Inc., check out Equities.com’s Stock Valuation Analysis report for ALXN. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.
The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.
While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.
For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer